Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
7 NC counties are under alert, including Johnston County.
Program
On WRAL at 6: Hidden fees in your childâs school lunch payment ð¨ð¸ 5 On Your Side shows you how to keep more money in your pocket
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bridgebio Pharma Inc
(NQ:
BBIO
)
25.66
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bridgebio Pharma Inc
< Previous
1
2
3
4
Next >
BridgeBio Pharma Inc. (NASDAQ: BBIO) Records 52-Week High Monday Morning
July 17, 2023
Via
Investor Brand Network
BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
July 17, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023
July 14, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Burjeel Holdings to Launch Rare Disease Research & Development Project ‘NADER’ in Partnership with US-based BridgeBio Pharma
July 12, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference
June 20, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 13, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference
June 08, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 22, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 15, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 11, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update
May 04, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference
April 27, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 11, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 07, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
March 23, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
March 21, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
March 17, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio's Volatile Week Puts Biotech Stocks Under a Microscope
March 14, 2023
BridgeBio’s recent volatility is a perfect example of how good news often turns into bad news for biopharmaceutical companies.
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
March 08, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
March 06, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events
March 06, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023
March 03, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update
February 23, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 17, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023
February 13, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Participate in February and March Investor Events
February 08, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference
January 04, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1
December 22, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Participate in November Investor Events
November 09, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update
November 03, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.